Literature DB >> 1322427

Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.

R S Rittmaster1, A Lemay, H Zwicker, T P Capizzi, S Winch, E Moore, G J Gormley.   

Abstract

Testosterone exerts negative feedback control on gonadotropin secretion either directly, after aromatization to estradiol, or after 5 alpha-reduction to dihydrotestosterone (DHT). Conflicting data exist as to the role of DHT in the modulation of this negative feedback. To determine whether suppression of endogenous DHT alters gonadotropin secretion, we gave the selective 5 alpha-reductase inhibitor finasteride (5 mg daily), or placebo, to 20 healthy men for 28 days. Basal and GnRH-stimulated LH, bioactive LH, FSH, testosterone, and DHT levels were measured before and after 14 and 28 days of treatment. Basal DHT fell from 1.1 +/- 0.2 to 0.15 +/- 0.04 nmol/L after 28 days of finasteride treatment. A significant rise in baseline testosterone from 17.6 +/- 2.0 to 18.3 +/- 2.3 nmol/L was seen at 14 days (P = 0.046), but not at 28 days. No significant changes were seen in either basal or GnRH-stimulated gonadotropin levels on any day. We conclude that suppression of serum DHT levels with 5 mg finasteride daily in healthy young men has no discernible effect on serum gonadotropin levels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322427     DOI: 10.1210/jcem.75.2.1322427

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  [Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

2.  5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.

Authors:  C-H Chou; C-L Lin; M-C Lin; F-C Sung; C-H Kao
Journal:  J Endocrinol Invest       Date:  2015-03-17       Impact factor: 4.256

3.  An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors.

Authors:  Matthew B Harrell; Kaylee Ho; Alexis E Te; Steven A Kaplan; Bilal Chughtai
Journal:  World J Urol       Date:  2020-06-28       Impact factor: 4.226

Review 4.  Adverse effects of common medications on male fertility.

Authors:  Mary K Samplaski; Ajay K Nangia
Journal:  Nat Rev Urol       Date:  2015-06-23       Impact factor: 14.432

Review 5.  [Treatment of LUTS in BPS. When and when not to administer pills?].

Authors:  R Berges
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

Review 6.  Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.

Authors:  D H Peters; E M Sorkin
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

7.  The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men.

Authors:  John K Amory; Bradley D Anawalt; Alvin M Matsumoto; Stephanie T Page; William J Bremner; Christina Wang; Ronald S Swerdloff; Richard V Clark
Journal:  J Urol       Date:  2008-04-18       Impact factor: 7.450

8.  Finasteride: a review of its use in male pattern hair loss.

Authors:  K J McClellan; A Markham
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

9.  Benign prostatic hyperplasia: An overview of existing treatment.

Authors:  Neelima Dhingra; Deepak Bhagwat
Journal:  Indian J Pharmacol       Date:  2011-02       Impact factor: 1.200

10.  Inhibitory effects of Serenoa repens on the kinetic of pig prostatic microsomal 5alpha-reductase activity.

Authors:  M F Palin; M Faguy; J G LeHoux; G Pelletier
Journal:  Endocrine       Date:  1998-08       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.